

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
 )  
OLIVER DANKE ET AL. )  
 )  
Serial No.: ~~Unassigned~~ 09/762691 )  
 )  
Filed: ~~Herewith~~ 2.9.01 )  
 )  
For: IN-VITRO METHOD FOR )  
 )  
DETECTING AND DIAG- )  
 )  
NOSING ACUTE CORONARY )  
 )  
SYNDROMES )

Group Art Unit: ~~Unknown~~ 1743  
Examiner: ~~Unknown~~ Cole

SADH  
#4  
7-17-01

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicants disclose the following information:

1. U.S. Patent No. 3,401,086, inventors Hoffmann et al., issued September 10, 1968;
2. Higuchi et al., "Mapping of Lactate and N-Acetyl-L-aspartate Predicts Infarction during Acute Focal Ischemia: In Vivo <sup>1</sup>H Magnetic Resonance Spectroscopy in Rats," Neurosurgery, 38(1):121-30 (January 1996);
3. Lauriero et al., "<sup>99</sup>Tc<sup>m</sup>-HMPAO SPET and <sup>1</sup>H-MRS (proton magnetic resonance spectroscopy) in patients with ischaemic cerebral infarction," Nuclear Medicine Communications, 17:140-6 (1996); and
4. Langton et al., "Serum phospholipase A<sub>2</sub> and lysolecithin changes following myocardial infarction," Clinica Chimica Acta, 205:223-31 (1992).

Copies of the foregoing documents are provided with this paper. In addition, these documents are listed on the enclosed PTO Form FB-A820. Applicants respectfully request that the

09/762691

532 Rec'd PCT/PTO 09 FEB 2001

Examiner consider the enclosed documents and evidence that consideration by making appropriate notations on the enclosed form.

This submission does not represent that a search has been made or that no better prior art exists and does not constitute an admission that the enclosed documents constitute "prior art."

Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the enclosed documents, should the documents be applied against the claims of the present invention.

If there are any fees due in connection with the filing of this paper that are not accounted for, the Examiner is authorized to charge the fees to our Deposit Account No. 11-1755. If a fee is required for an extension of time under 37 C.F.R. 1.136 that is not accounted for already, such an extension of time is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Kriegsman & Kriegsman

By: Edward M. Kriegsman

Edward M. Kriegsman  
Reg. No. 33,529  
883 Edgell Road  
Framingham, MA 01701  
(508) 877-8588

Dated: February 9, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on \_\_\_\_\_.

\_\_\_\_\_  
Edward M. Kriegsman  
Reg. No. 33,529  
Dated: \_\_\_\_\_